Nevertheless, WHO 2022 provided a caveat that the detection of ≥15% ring sideroblasts may substitute for SF3B1 mutation and stated that an acceptable related terminology for this would be MDS with low blasts and ring sideroblasts in the absence of an SF3B1 mutation [10]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.